alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › placebo-controlled-double-blind

placebo-controlled-double-blind

2 studies tagged placebo-controlled-double-blind, dated 2008-11-29 to 2011-03-01. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. EHT0202 in Alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study 2011-03-01
  2. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial 2008-11-29

Studies

2 studies carry this tag.

Date range

2008 to 2011

Top journals

  • Current Alzheimer research 1
  • The Lancet. Neurology 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. EHT0202 in Alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study

    ✓ Peer-reviewed alzhub usefulness score 71 out of 100. Current Alzheimer research 2011-03-01 Treatments

    These first encouraging safety results do support further development of EHT0202 in order to assess its clinical efficacy and to confirm its tolerability in a larger cohort of Alzheimer patients and for a longer period.

  2. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial

    ✓ Peer-reviewed alzhub usefulness score 71 out of 100. The Lancet. Neurology 2008-11-29 Treatments

    168 of 207 (81%) patients in the galantamine group and 161 of 200 (81%) in the placebo group completed the study.

All topic tags with their study counts